Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Probiotics wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
30 of 39 studies with measurable effects showed benefit.
Top outcomes
10-20mg daily
morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
10-20 billion CFU
With or without food (strain-dependent), Same time daily for consistency
Capsules with multiple strains
Acute to 6 weeks
4 weeks
12 months
3 weeks
2-4 weeks
4-8 weeks
4-8 weeks
First 1-2 weeks
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
Preventive Effect of Probiotics on Oral Mucositis Induced by Cancer Treatment: A Systematic Review and Meta-Analysis
International journal of molecular sciences (2022) · Meta analysis · n=708
Three trials using Lactobacilli-based probiotics reported that the incidence of oral mucositis in the probiotic group was significantly low (risk ratio [RR] = 0.84, 95% confidence interval [CI] = 0.77−0.93, p = 0.0004).
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
The Cochrane database of systematic reviews (2017) · Meta analysis · n=9955
A complete case analysis (i.e. participants who completed the study) among trials investigating CDAD (31 trials, 8672 participants) suggests that probiotics reduce the risk of CDAD by 60%.
Based on meta-analyses showing benefits for IBS and digestive symptoms. Effect sizes varied considerably between studies with low to very low certainty of evidence. Initial GI symptoms common when starting but typically resolve within 1-2 weeks.
AI-estimated from published studies. Interpret as directional guidance.
Probiotics has a higher evidence score (9/10 vs 5/10) and wins in 2 of 3 categories.
For reduce inflammation, Probiotics has a higher relevance score (95 vs 45).
No known interactions between MitoQ and Probiotics have been documented in our database. However, always consult a healthcare provider before combining supplements.